Ingenix

Ingenix. ai Sp z o. o. offers generative AI solutions tailored for clinical development, enhancing drug discovery processes through advanced simulation techniques.

Ingenix. ai Sp z o. o. was founded in 2023 in Warsaw, Poland, focusing on AI-powered clinical trial simulations.

As of April 8, 2025, when it raised EUR 9 million in Seed funding led by Inovo VC, with participation from International Finance Corporation and OTB Ventures. In June 2026, Ingenix raised EUR 13 million in seed funding led by Sofinnova Partners, with participation from Inovo VC and OTB Ventures. The company was founded by individuals whose specific identities are not publicly detailed, and there are no mentions of previous companies established by them. Ingenix offers a proprietary multimodal and multiscale generative AI platform designed specifically for clinical development.

The core product, Ingenix, functions as a co-pilot for simulating clinical trials using advanced chain-of-thought prompting techniques. It integrates diverse biological and medical knowledge through various modalities, including text, graphics, bioimaging, and 3D structures. The platform aims to address the complexities of drug development by providing granular predictions of clinical endpoint values and adverse events, enabling clinical investigators to optimize drug candidate selection and make informed decisions. Ingenix serves a range of stakeholders across the pharmaceutical industry, including pre-clinical development teams, strategy teams, and clinical development teams, primarily focusing on markets in North America and Europe.

Ingenix generates revenue through partnerships with pharmaceutical companies and clinical research organizations, offering subscription-based access to its AI platform. Transaction structures typically involve B2B agreements where clients pay for access to the platform on an annual or project basis, depending on the scope of their research needs. The platform's flagship service allows clients to leverage its advanced predictive capabilities for drug development, thereby streamlining their research processes. Specific pricing plans for the service are determined based on the scale of usage and the complexity of the services required, aligning with the unique needs of each client.

By facilitating data-driven insights, Ingenix positions itself as an essential tool in the burgeoning field of AI-assisted drug discovery. In April 2025, Ingenix. ai Sp z o. o.

raised EUR 9 million in Seed funding led by new investor Inovo VC, with participation from other new investors OTB Ventures and International Finance Corporation. The company will use the funding to advance the development of its artificial intelligence-powered clinical trial simulation technology and enhance its predictive modeling capabilities for drug development. The company will use the June 2026 funding to advance its Biological Reasoning Engine and expand partnerships with pharma and biotech firms through its Qualified Access Program.